Exact Sciences Raises $8.2M

Wade Roush6/12/09

In a private placement of stock, Marlborough, MA-based Exact Science (NASDAQ: EXAS) has raised $8.2 in new funding, according to an announcement today. The company, which has developed a molecular screening test for colorectal cancer, also said it has licensed technology developed by cancer researcher David Ahlquist at the Mayo Clinic covering aspects of sample processing and data analysis related to DNA screening for the disease.

Wade Roush is Xconomy's chief correspondent and editor of Xconomy San Francisco. You can e-mail him at wroush@xconomy.com or follow him on Twitter at twitter.com/wroush.